Mezzion Pharma Reports Positive In Vivo Study Results for Udenafil in ADPKD

Mezzion Pharma Co., Ltd. has announced positive results from a new in vivo study of udenafil, a phosphodiesterase type 5 (PDE5) inhibitor, in autosomal dominant polycystic kidney disease (ADPKD).

The study utilized a preclinical ADPKD model, where udenafil demonstrated potential in reducing kidney cyst growth and improving renal function. The company has gathered promising data regarding the drug's effects on disease progression.

ADPKD is an inherited disorder that leads to declining kidney function and can result in kidney failure. The development of new treatments is significant, as current therapeutic options are limited. Mezzion's research contributes to broader efforts to find more effective therapies for this patient population.

The company plans to continue its research and development efforts for the drug. Future steps are expected to involve further preclinical studies and potentially human clinical trials to assess safety and efficacy.